Summary
Pfizer Inc. reported a solid financial performance for the second quarter and first six months of 2002, showcasing revenue growth driven primarily by sales volume in its key pharmaceutical products. The company demonstrated a strong increase in net income and earnings per share compared to the prior year, reflecting robust operational execution and effective cost management, even with increased R&D and SI&A expenses to support its product pipeline and launches. The company's financial strength is further underscored by healthy cash flow from operations and a significant increase in short-term investments. Notably, Pfizer announced a major strategic move with the definitive agreement to merge with Pharmacia Corporation, valued at approximately $60 billion, indicating a strong growth outlook and commitment to expanding its market presence. Additionally, the company continues its aggressive share repurchase program and has strategically reviewed its consumer product businesses, signaling a focus on optimizing its portfolio.
Key Highlights
- 1Revenues increased by 5.4% to $8.03 billion for the second quarter and 8.2% to $16.45 billion for the first six months of 2002 compared to the prior year periods.
- 2Net income for the second quarter rose 7% to $1.96 billion, and for the first six months, it increased 4% to $3.92 billion, with diluted EPS growing to $0.32 and $0.62, respectively.
- 3The pharmaceutical segment remains the primary revenue driver, with key products like Lipitor, Norvasc, and Zoloft showing strong growth.
- 4Pfizer announced a definitive agreement to merge with Pharmacia Corporation in a stock-for-stock transaction valued at approximately $60 billion, expected to close by year-end 2002.
- 5The company significantly increased its share-purchase program authorization from $10 billion to $16 billion, demonstrating commitment to returning capital to shareholders.
- 6Merger-related costs, primarily integration and restructuring charges from the Warner-Lambert acquisition, decreased significantly compared to the prior year.
- 7The company is exploring strategic options, including potential sales, for its Adams confectionery, Schick-Wilkinson Sword shaving products, and Tetra aquarium businesses.